kidney cancer news from FierceBiotech
News
A deluge of pre-ASCO data hits the market
As we mentioned earlier this week, data from almost 5,000 clinical studies was released last night in preparation for next week's ASCO meeting. And some of the most interesting data won't be released Read more...
Report: Wilex, GPC nearing merger pact
Two German biotech companies which share a very big investor are preparing to merge, according to a prominent German newspaper. Wilex and GPC Biotech, both involved in developing new cancer Read more...
Antigenics gets world's first cancer vaccine approval
Russia has improbably emerged as a world leader in new cancer vaccines. The country's regulatory body approved the use of Read more...
Novartis ends cancer trial early after hitting endpoint
Novartis has brought a late-stage study of its kidney cancer drug everolimus to a premature close after an independent review committee determined the therapy had extended patients' lives without Read more...
ALSO NOTED: Biogen snares first start-up for incubator; Alkermes gains from Reliance sale; Galapagos inks deal with Lilly; and
> Biogen Idec has announced the first "occupant" in its Biogen Idec Innovation Incubator (bi3): Escoublac, a startup founded on the discovery of a new link between bone biology and metabolism. The Read more...
ALSO NOTED: Anadys names new CEO; Pfizer, Amgen gives to candidates; and much more...
> In the midst of a restructuring, Anadys Pharmaceuticals has named Steve Worland CEO. He had been head of pharmaceuticals. Read more...
Press Release: Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Press Release: Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Read more...Galil Medical gains $52M in VC
Thomas, McNerney and The Vertical Group have led a $52 million venture round for Israel's Galil Medical. Galil Medical develops and markets a cryotherapy platform that uses freezing technology and proprietary needle design for treating prostate and kidney cancer as well as other conditions. Galil has more than $20 million in annual revenue.
"We are now well positioned both organizationally and financially, to expand our global sales and marketing activities as well as to invest in …
Read more...Bayer, Onyx announce disappointing Nexavar results
In a late-stage disappointment, Bayer and partner Onyx Pharmaceuticals have announced that their skin cancer drug Nexavar did not meet the primary endpoint of progression-free survival. Nexavar, which has received both Fast Track and Orphan Drug Status, was approved last year as a therapy for advanced renal-cell carcinoma. Previously, Bayer and Onyx also announced that a …
Read more...ALSO NOTED: Nektar closes UK site; Martines resigns from NSP; and much more...
> Nektar Therapeutics has closed a site in the U.K. that employs 35 workers. Report
> Chutes & Ladders: Sergio Martines has resigned as a director, president and CEO of NSP Pharma. Release
> Inspire Pharmaceuticals has launched a Phase III clinical …
Read more...Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends